Indian Journal of Endocrinology and Metabolism

ORIGINAL ARTICLE
Year
: 2015  |  Volume : 19  |  Issue : 4  |  Page : 483--490

An observational study to assess back pain in patients with severe osteoporosis treated with teriparatide versus antiresorptives: An Indian subpopulation analysis


Harvinder Chhabra1, Rajesh Malhotra2, Sunil Marwah3, Bharat Dave4, Kyoungah See5, Simrat Sohal6, Sirel Gurbuz7 
1 Medical Director and Chief of Spine Services, Indian Spinal Injuries Centre, All India Institute of Medical Sciences, New Delhi, India
2 Consultant Orthopedic Surgeon, All India Institute of Medical Sciences, New Delhi, India
3 Orthopedic Surgeon, Marwah Clinic, Gurgaon, India
4 Orthopedic Surgeon, Stavya Spine Hospital and Research Institute, Ellisbridge, Ahmedabad, India
5 Principal Research Scientist, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, USA
6 Ethics and Compliance Officer, Eli Lilly and Company (India) Pvt. Ltd., Gurgaon, India
7 Senior Medical Advisor, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, USA

Correspondence Address:
Dr. Sirel Gurbuz
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285
USA

Background: One year, prospective, observational study in an Indian subpopulation to assess back pain in patients with severe osteoporosis treated with teriparatide or antiresorptives in a clinical setting. Materials and Methods: One hundred and nineteen teriparatide-naοve Indian men and postmenopausal women (mean age 68.0 years) with previous osteoporotic vertebral fracture participated. Patients were assessed at baseline, 6-and 12-months to evaluate relative risk (RR) of new/worsening back pain using the Back Pain Questionnaire. The incidence of back pain and changes in back pain severity were assessed using the visual analog scale (VAS); Health outcomes were assessed using the euroquol-5 dimensions (EQ-5D) questionnaire. All tests were conducted with a two-sided alpha of 0.05. Results: Of 562 overall patients, 57, 60, and 2 Indian patients received teriparatide, antiresorptive, or teriparatide and antiresorptive, respectively. Baseline disease characteristics were slightly worse for antiresorptive-treated patients, whereas teriparatide-treated patients were older with more comorbidities. At 6-months, the incidence of new/worsening back pain was 5.3% for teriparatide-treated patients versus 4.4% for antiresorptive-treated patients (RR: 1.00, 95% confidence interval: 0.68, 1.48); the incidence of severe back pain was 0% versus 12.5% (P = 0.017); in these treatment groups, respectively. Mean VAS change scores (mean ± standard deviation [SD]) were − 1.9 ± 1.73 versus − 1.4 ± 1.77, and mean EQ-5D change scores were 4.2 ± 27.20 versus 9.9 ± 26.23 at 6-months. At 6 months, more teriparatide-treated patients felt better (89% vs. 61%; P = 0.001) and were at least very satisfied with their treatment (30% vs. 9%; P = 0.011). Conclusion: Teriparatide-treated Indian patients had similar new/worsening back pain risk and minimal risk of severe back pain compared with antiresorptive-treated patients at 6-months.


How to cite this article:
Chhabra H, Malhotra R, Marwah S, Dave B, See K, Sohal S, Gurbuz S. An observational study to assess back pain in patients with severe osteoporosis treated with teriparatide versus antiresorptives: An Indian subpopulation analysis.Indian J Endocr Metab 2015;19:483-490


How to cite this URL:
Chhabra H, Malhotra R, Marwah S, Dave B, See K, Sohal S, Gurbuz S. An observational study to assess back pain in patients with severe osteoporosis treated with teriparatide versus antiresorptives: An Indian subpopulation analysis. Indian J Endocr Metab [serial online] 2015 [cited 2021 Sep 20 ];19:483-490
Available from: https://www.ijem.in/article.asp?issn=2230-8210;year=2015;volume=19;issue=4;spage=483;epage=490;aulast=Chhabra;type=0